"Benzenesulfonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic salts and esters of benzenesulfonic acid.
| Descriptor ID |
D001557
|
| MeSH Number(s) |
D02.455.426.559.389.097 D02.886.645.600.080.050.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzenesulfonates".
Below are MeSH descriptors whose meaning is more specific than "Benzenesulfonates".
This graph shows the total number of publications written about "Benzenesulfonates" by people in this website by year, and whether "Benzenesulfonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzenesulfonates" by people in Profiles.
-
Deposition and release kinetics of nano-TiO2 in saturated porous media: effects of solution ionic strength and surfactants. Environ Pollut. 2013 Mar; 174:106-13.
-
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
-
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
-
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011 Mar 01; 11(5):524-34.
-
Aggregation and transport of nano-TiO2 in saturated porous media: effects of pH, surfactants and flow velocity. Water Res. 2011 Jan; 45(2):839-51.
-
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010 Aug; 9(8):2220-31.
-
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010 Aug 01; 70(15):6313-24.
-
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec; 29(6):1132-42.
-
Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract. 2010 May-Jun; 16(3):441-5.
-
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther. 2009 Dec; 8(24):2406-16.